{"id":2503,"date":"2021-06-30T11:12:52","date_gmt":"2021-06-30T11:12:52","guid":{"rendered":"https:\/\/ibcc.clinic\/?p=2503"},"modified":"2021-08-09T11:14:03","modified_gmt":"2021-08-09T11:14:03","slug":"her2-enriched-subtype-and-erbb2-expression-in-her2-positive-breast-cancer-treated-with-dual-her2-blockade","status":"publish","type":"post","link":"https:\/\/ibcc.clinic\/en\/her2-enriched-subtype-and-erbb2-expression-in-her2-positive-breast-cancer-treated-with-dual-her2-blockade\/","title":{"rendered":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[33],"tags":[],"class_list":["post-2503","post","type-post","status-publish","format-standard","hentry","category-publications-archive"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade - International Breast Cancer Center<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade - International Breast Cancer Center\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/\" \/>\n<meta property=\"og:site_name\" content=\"International Breast Cancer Center\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-30T11:12:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-08-09T11:14:03+00:00\" \/>\n<meta name=\"author\" content=\"Carles\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Carles\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/\"},\"author\":{\"name\":\"Carles\",\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#\\\/schema\\\/person\\\/e7725ab9f7c6e7eee62c673b16432cdc\"},\"headline\":\"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade\",\"datePublished\":\"2021-06-30T11:12:52+00:00\",\"dateModified\":\"2021-08-09T11:14:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/\"},\"wordCount\":16,\"publisher\":{\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#organization\"},\"articleSection\":[\"Publications Archive\"],\"inLanguage\":\"en-US\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/\",\"url\":\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/\",\"name\":\"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade - International Breast Cancer Center\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#website\"},\"datePublished\":\"2021-06-30T11:12:52+00:00\",\"dateModified\":\"2021-08-09T11:14:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"IBCC\",\"item\":\"https:\\\/\\\/ibcc.clinic\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications Archive\",\"item\":\"https:\\\/\\\/ibcc.clinic\\\/en\\\/IBCC\\\/publications-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#website\",\"url\":\"https:\\\/\\\/ibcc.clinic\\\/\",\"name\":\"International Breast Cancer Center\",\"description\":\"El primer centro hiperespecializado en c\u00e1ncer de mama de Espa\u00f1a\",\"publisher\":{\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibcc.clinic\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#organization\",\"name\":\"IBCC\",\"url\":\"https:\\\/\\\/ibcc.clinic\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ibcc.clinic\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/IBCC_logo_vertica_1l.png\",\"contentUrl\":\"https:\\\/\\\/ibcc.clinic\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/IBCC_logo_vertica_1l.png\",\"width\":498,\"height\":500,\"caption\":\"IBCC\"},\"image\":{\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibcc.clinic\\\/#\\\/schema\\\/person\\\/e7725ab9f7c6e7eee62c673b16432cdc\",\"name\":\"Carles\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade - International Breast Cancer Center","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/","og_locale":"en_US","og_type":"article","og_title":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade - International Breast Cancer Center","og_url":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/","og_site_name":"International Breast Cancer Center","article_published_time":"2021-06-30T11:12:52+00:00","article_modified_time":"2021-08-09T11:14:03+00:00","author":"Carles","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Carles"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/#article","isPartOf":{"@id":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/"},"author":{"name":"Carles","@id":"https:\/\/ibcc.clinic\/#\/schema\/person\/e7725ab9f7c6e7eee62c673b16432cdc"},"headline":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade","datePublished":"2021-06-30T11:12:52+00:00","dateModified":"2021-08-09T11:14:03+00:00","mainEntityOfPage":{"@id":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/"},"wordCount":16,"publisher":{"@id":"https:\/\/ibcc.clinic\/#organization"},"articleSection":["Publications Archive"],"inLanguage":"en-US"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/","url":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/","name":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade - International Breast Cancer Center","isPartOf":{"@id":"https:\/\/ibcc.clinic\/#website"},"datePublished":"2021-06-30T11:12:52+00:00","dateModified":"2021-08-09T11:14:03+00:00","breadcrumb":{"@id":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibcc.clinic\/subtipo-enriquecido-con-her2-y-expresion-de-erbb2-en-cancer-de-mama-her2-positivo-tratado-con-bloqueo-dual-de-her2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"IBCC","item":"https:\/\/ibcc.clinic\/"},{"@type":"ListItem","position":2,"name":"Publications Archive","item":"https:\/\/ibcc.clinic\/en\/IBCC\/publications-archive\/"},{"@type":"ListItem","position":3,"name":"HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade"}]},{"@type":"WebSite","@id":"https:\/\/ibcc.clinic\/#website","url":"https:\/\/ibcc.clinic\/","name":"International Breast Cancer Center","description":"El primer centro hiperespecializado en c\u00e1ncer de mama de Espa\u00f1a","publisher":{"@id":"https:\/\/ibcc.clinic\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibcc.clinic\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/ibcc.clinic\/#organization","name":"IBCC","url":"https:\/\/ibcc.clinic\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibcc.clinic\/#\/schema\/logo\/image\/","url":"https:\/\/ibcc.clinic\/wp-content\/uploads\/2020\/12\/IBCC_logo_vertica_1l.png","contentUrl":"https:\/\/ibcc.clinic\/wp-content\/uploads\/2020\/12\/IBCC_logo_vertica_1l.png","width":498,"height":500,"caption":"IBCC"},"image":{"@id":"https:\/\/ibcc.clinic\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ibcc.clinic\/#\/schema\/person\/e7725ab9f7c6e7eee62c673b16432cdc","name":"Carles"}]}},"_links":{"self":[{"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/posts\/2503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/comments?post=2503"}],"version-history":[{"count":1,"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/posts\/2503\/revisions"}],"predecessor-version":[{"id":2504,"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/posts\/2503\/revisions\/2504"}],"wp:attachment":[{"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/media?parent=2503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/categories?post=2503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibcc.clinic\/en\/wp-json\/wp\/v2\/tags?post=2503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}